ADVISORY, Dec. 12, 2014 (GLOBE NEWSWIRE) --
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, will visit the Nasdaq MarketSite in Times Square. The Company’s initial focus is on the development of ZS-9, a product candidate in Phase 3 development for the treatment of hyperkalemia.
In honor of the occasion, Robert Alexander, Ph.D., Chief Executive Officer will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Monday, December 15, 2014 – 9:15 a.m. to 9:30 a.m. ET
ZS Pharma, Inc. Media Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A webcast of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About ZS Pharma, Inc. (Nasdaq:ZSPH):
ZS Pharma is a publicly-traded, specialty pharmaceutical company based in Coppell, Texas. ZS Pharma’s lead therapeutic candidate, ZS-9, is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases. Additional information is available at www.zspharma.com.
The Company’s initial focus is on the development of ZS-9, a product candidate in Phase 3 development for the treatment of hyperkalemia. Hyperkalemia is characterized by elevated levels of potassium in the blood and is a potentially life-threatening condition that occurs frequently in patients with chronic kidney disease (CKD), heart failure, and diabetes. Hyperkalemia can also arise from the use of RAAS inhibitors, which are commonly prescribed for patients with hypertension, heart failure and CKD. Currently there is a lack of effective, safe and tolerable treatments for hyperkalemia.
The Company recently completed a Phase 3 clinical trial, HARMONIZE, that over a longer treatment period, confirmed the positive results from its first Phase 3 clinical trial, ZS003. With two Phase 3 trials completed and additional long-term safety studies, ZS004E and ZS005, underway, the Company plans to file a New Drug Application (NDA) with the United States Food and Drug Administration and a Marketing Authorization Application (MAA) with the European Medicines Agency in the first half of 2015.
In June of this year, ZS Pharma closed its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.